Gilead-Bristol Hepatitis C Drug Combo Cures All in Study
This article is for subscribers only.
A hepatitis C drug combination from Gilead Sciences Inc. and Bristol-Myers Squibb Co. cured all patients in a trial, demonstrating the success of a cocktail that may never be approved.
In a study among 41 patients of Gilead’s sofosbuvir with Bristol’s daclatasvir, with or without the generic antiviral ribavirin, 40 were virus-free 12 weeks after six months of treatment, according to results presented yesterday in Amsterdam. The other patient didn’t turn up to the last appointment and was later found to be virus-clear. All the patients had failed prior treatment with either Vertex Pharmaceuticals Inc.’s Incivek or Merck & Co.’s Victrelis.